Bexson Biomedical Issued USPTO Patent on Proprietary Formulation Technology, SEVALENT™
2023-01-09
SANTA BARBARA, Calif., Jan. 9, 2023 /PRNewswire/ -- Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent 11,534,454 titled Complexing Agent Salt Formulations of Pharmaceutical Compounds.
Bexson's formulation technology, branded as SEVALENT™, is the basis for the Company's lead therapy utilizing ketamine for post-operative pain management. This patent now expands the potential utility of its technology to a broad range of additional small molecules enabling intravenous (IV)-only therapies to be delivered subcutaneously in a controlled manner for use in the home setting.
"This patent is critical in protecting our novel salt formulation, SEVALENT™, across an extensive range of therapeutic areas," commented Jeffrey Becker, MD, Chief Scientific Officer. "We believe SEVALENT™ creates the opportunity to migrate a wide variety of small molecule therapies from IV to subcutaneous administration which will be a game changer for both patients and payors."
"We are pleased with this step forward in building out the Company's patent portfolio and achieving another important milestone in protecting our formulation technology," said Gregg Peterson, CEO. "In addition, this patent further strengthens our intellectual property position and underscores our strong commitment to innovation in advancing subcutaneous delivery of small molecule therapies."
Bexson Biomedical, Inc. is a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions through new formulations designed for subcutaneous delivery. Bexson's proprietary platform, SEVALENT™, can be applied to small molecules across a broad range of drug classes, enabling IV therapies to be delivered subcutaneously.
SOURCE Bexson Biomedical
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
靶点
-来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。